Piper Sandler Forecasts Strong Price Appreciation for CME Group (NASDAQ:CME) Stock

CME Group (NASDAQ:CME) had its target price boosted by analysts at Piper Sandler from $313.00 to $329.00 in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage presently has an “overweight” rating on the financial services provider’s stock. Piper Sandler’s target price suggests a potential upside of 11.07% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley increased their price objective on shares of CME Group from $340.00 to $362.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Argus reissued a “hold” rating on shares of CME Group in a research report on Wednesday, March 4th. Jefferies Financial Group lowered their target price on shares of CME Group from $356.00 to $349.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft upped their target price on shares of CME Group from $312.00 to $316.00 and gave the stock a “buy” rating in a report on Thursday, February 5th. Finally, Erste Group Bank upgraded shares of CME Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $309.94.

CME Group Price Performance

CME stock opened at $296.22 on Wednesday. The stock has a market capitalization of $106.23 billion, a PE ratio of 26.54, a price-to-earnings-growth ratio of 3.05 and a beta of 0.26. The company’s 50-day moving average is $306.66 and its 200-day moving average is $285.27. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.03 and a quick ratio of 1.03. CME Group has a 1 year low of $251.90 and a 1 year high of $329.16.

CME Group (NASDAQ:CME) last released its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.75 by $0.02. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.64 billion. CME Group had a net margin of 62.45% and a return on equity of 14.65%. The business’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.52 EPS. Equities research analysts expect that CME Group will post 10.49 EPS for the current fiscal year.

Insider Activity

In other CME Group news, Director Bryan T. Durkin sold 4,200 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $309.65, for a total value of $1,300,530.00. Following the completion of the sale, the director owned 43,007 shares in the company, valued at approximately $13,317,117.55. This trade represents a 8.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Dennis Suskind sold 748 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $300.00, for a total transaction of $224,400.00. Following the completion of the sale, the director owned 2,699 shares of the company’s stock, valued at approximately $809,700. This trade represents a 21.70% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 8,539 shares of company stock worth $2,713,821. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On CME Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in CME. Empowered Funds LLC increased its stake in CME Group by 11.5% in the 1st quarter. Empowered Funds LLC now owns 10,027 shares of the financial services provider’s stock valued at $2,660,000 after buying an additional 1,037 shares during the last quarter. Marshall Wace LLP increased its stake in shares of CME Group by 103.1% during the 2nd quarter. Marshall Wace LLP now owns 3,692 shares of the financial services provider’s stock worth $1,018,000 after purchasing an additional 121,707 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of CME Group by 1,325.2% during the 2nd quarter. Federated Hermes Inc. now owns 23,572 shares of the financial services provider’s stock worth $6,497,000 after purchasing an additional 21,918 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in shares of CME Group during the 2nd quarter worth approximately $992,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of CME Group by 2.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 287,876 shares of the financial services provider’s stock worth $79,344,000 after purchasing an additional 7,397 shares during the last quarter. Hedge funds and other institutional investors own 87.75% of the company’s stock.

More CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Regulatory approval for expanded U.S. Treasury cross‑margining with DTCC should lower client capital needs and deepen ties with fixed‑income clearing users, potentially boosting transaction volumes and stickiness. DTCC and CME cross‑margining approval
• Positive Sentiment: ESMA recognition of CME Group Benchmark Administration as a third‑country benchmark administrator validates Term SOFR usage in Europe and supports international distribution of CME’s rates products. ESMA recognition of CBA
• Positive Sentiment: CME is expanding its Equity Index Dividend suite (mid‑curve options and quarterly futures) and will add options on Eris SOFR swap futures — product launches that broaden revenue opportunities in equity and rates derivatives. Equity Index Dividend expansion Options on Eris SOFR swap futures
• Neutral Sentiment: Zacks and other outlets highlight expectations for earnings growth ahead of results — a potential catalyst if CME posts beats, but already priced partly into a relatively high P/E. Zacks earnings preview
• Neutral Sentiment: Institutional flows are mixed: large buys by some managers offset by big trims from others (e.g., UBS AM notably reduced exposure), leaving ownership rotation that can amplify intraday moves. QuiverQuant institutional holdings/flows
• Neutral Sentiment: Developments in decentralized finance/tokenized equities (Hyperliquid’s rapid growth in tokenized equity perps) are a watch item — potential long‑term competition for tradable equity derivatives but not an immediate revenue hit. Hyperliquid tokenized equity growth
• Negative Sentiment: CFTC is investigating suspicious oil futures trades on CME/ICE tied to geo‑political events — a regulatory probe that could create reputational risk, lead to compliance costs or tighter oversight. CFTC probe into oil futures trades MSN coverage
• Negative Sentiment: Significant insider selling (including CEO Terrence Duffy and other senior managers) and limited insider buys could signal management monetization and is likely weighing on sentiment. QuiverQuant insider trades & lobbying
• Negative Sentiment: Analyst views are mixed: Piper Sandler raised its target and kept an Overweight (positive signal), but JPMorgan maintains an Underweight and cut its downside target only slightly higher — plus recent notes from Rothschild & Co Redburn and Barclays lowered expectations, adding downward pressure. JPMorgan price target Piper Sandler target update Rothschild & Co Redburn note
• Neutral Sentiment: Lobbying disclosure (~$430k in Q1) shows CME is actively engaging regulators on clearing, digital assets and tax/treatment of futures — signals policy risk management but also highlights areas where outcomes could materially affect future revenue. Lobbying disclosure

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.